New diabetes clinical trial: A Randomized Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Published on: October 21, 2025 at 11:00PM
Conditions: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)
Interventions: Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Drug: Obicetrapib 10 mg; Other: Placebo
Sponsors: NewAmsterdam Pharma
Not yet recruiting
https://ift.tt/NYkw2Pp
Conditions: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)
Interventions: Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Drug: Obicetrapib 10 mg; Other: Placebo
Sponsors: NewAmsterdam Pharma
Not yet recruiting
https://ift.tt/NYkw2Pp
Comments
Post a Comment